TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride
Description: Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20mg daily for 5 years or until relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Tamoxifen 20mg daily for 5 years or until relapse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Description: Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy
Description: Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
Study: NCT00398827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03420417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal pressure measurement
Description: Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
Study: NCT03805906

Intervention type: PROCEDURE
Intervention: L5 Dorsal ramus block
Description: Ultrasound-guided L5 dorsal ramus block
Study: NCT00884533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosi XR
Description: Rosi XR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04221594

Intervention type: PROCEDURE
Intervention: Coronary Computed Tomographic Angiogram (CCTA)
Description: Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.

Intervention type: PROCEDURE
Intervention: Dynamic Cardiac Positron Emission Tomography (dPET)
Description: Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
Study: NCT01132417

Intervention type: DRUG
Intervention: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
Description: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
Study: NCT04523480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testopel 75mg Drug Implant
Description: 75 mg Testosterone pellets administered subcutaneously.
Study: NCT00884533

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg single dose
Study: NCT00488072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: 15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet by mouth daily.
Study: NCT03467607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tidal volume ventilation
Description: low tidal volume ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tidal volume ventilation
Description: low tidal volume ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tidal volume ventilation
Description: low tidal volume ventilation
Study: NCT00570414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: Airway management by the use of the flexible, reinforced laryngeal mask airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Airway management by the use of endotracheal tube
Study: NCT00880373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo three times daily for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamorphine or Morphine
Description: Diamorphine or Morphine by PCA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diamorphine or Morphine
Description: Diamorphine or Morphine by PCA
Study: NCT03003611

Intervention type: PROCEDURE
Intervention: hypnose sedation
Description: Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia

Intervention type: PROCEDURE
Intervention: general anesthesia
Description: Patient will be anesthetized with a classical general anesthesia
Study: NCT03149510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Participants will use the mobile application daily to assess heart failure symptoms.
Study: NCT04523480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testopel 100mg Drug Implant
Description: 100 mg Testosterone pellets administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testopel 200mg Drug Implant
Description: 200 mg Testosterone pellets administered subcutaneously.
Study: NCT02726386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612
Description: ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612
Description: ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Study: NCT03168906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline bag
Study: NCT03458364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
Study: NCT02707887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LETS ACT
Description: The Life Enhancement Treatment for Substance Use (LETS ACT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LETS ACT-SE
Description: Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive the treatment typically provided to patients at the substance use treatment facility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive the treatment typically provided to patients at the substance use treatment facility.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive the treatment typically provided to patients at the substance use treatment facility.
Study: NCT03544840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Home Program
Description: On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
Study: NCT04108962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasenra, 30 Mg/mL Subcutaneous Solution
Description: Anti-IL5 receptor alpha monoclonal antibody
Study: NCT03866928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stiripentol
Description: 1500 mg of stiripentol b.i.d.
Study: NCT01422486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezatiostat hydrochloride (Telintra®)
Description: Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
Study: NCT01774682

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 6-minute walk test
Description: the test corresponds to that defined by Abdel Kafi et al in 2005
Study: NCT03267654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib combined with chemotherapy
Description: Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib combined with apatinib
Description: gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib single agent
Description: Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
Study: NCT02522780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Pharmaceutical form: Granules in sachet; Route of administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Granules in sachet; Route of administration: Oral use
Study: NCT01715649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose
Description: In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
Study: NCT01513395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval bladder emptying
Description: Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time.
Study: NCT00526162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-ventricular Implantable Cardioverter Defibrillator
Description: Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
Study: NCT00002784

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy
Description: radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
Study: NCT01230034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: pill, 5 and 10 mg/day, od, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidapril
Description: pill, 10 and 20 mg/day, od, 24 weeks
Study: NCT01983670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal electrical stimulation
Study: NCT03786354

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3DCRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT00875082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast, chewing tablets 5mg, once daily, 8 weeks
Study: NCT03841708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleth variability index
Description: The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above\>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
Study: NCT00875082

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
Study: NCT03841708

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard non invasive monitoring
Description: In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
Study: NCT03743922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calciferol
Description: calciferol capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT03869853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrepreneurial stimulation and integrated education
Description: one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention
Study: NCT03795974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: Hematopoietic stem cells derived from allogenic umbilical cord

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MNC
Description: Hematopoietic stem cells derived from allogenic umbilical cord

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: Mesenchymal cells derived from allogenic umbilical cord

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC
Description: Mesenchymal cells derived from allogenic umbilical cord

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
Study: NCT06232161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red-light therapy device
Description: Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles
Description: Single focus spectacles, that is to say, wearing glasseses with minus power lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Single focus spectacles, that is to say, wearing glasseses with minus power lens
Study: NCT00264589

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 8 weeks individualized training program
Description: no drugs added
Study: NCT01188317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: repeated daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: repeated daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: repeated daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibuprofen
Description: repeated daily doses
Study: NCT01734811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological vaccine
Description: daily spray (2 puff of 100 µL) for six months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological vaccine
Description: daily spray (2 puff of 100 µL) for six months